Alan Breier, M.D.
Alan Breier, M.D.
|Personal Statement||Schizophrenia is one of the most severe and puzzling disorders in all medicine. Advances in brain imaging, genomics and translational sciences has led to the brink of major breakthroughs in understanding the cause of schizophrenia and the development of innovative therapeutics for its treatment. Central Indiana offers an ideal professional environment to accelerate the acquisition of new knowledge that will ultimately benefit the countless patients in our State and around the world.|
|Education||Undergraduate: University of Toledo
Medical School: University of Cincinnati College of Medicine
Residency: Yale University School of Medicine
Fellowship: Clinical Neuroscience Branch, NIMH
Diplomate, National Board of Medical Examiners
Diplomate, The American Board of Psychiatry and Neurology
|Current Academic Interests||Teaching: Involved in teaching medical students, psychiatry residents and fellows at Larue D. Carter Memorial Hospital and Prevention and Recovery Center for Early Psychosis (PARC) of Wishard Hospital as the Professor of Psychiatry, Chief, Psychotic Disorders Program.
Clinical: Supervises the clinical care of patients with severe psychiatric disablers at Larue Carter Memorial Hospital and the newly established Prevention and Recover Center for Early Psychosis (PARC) at Wishard Hospital
Research: The primary research focus involves testing innovative therapeutics for schizophrenia and elucidating the underlying disease processes of psychotic disorders. Genetic analyses and brain imaging are used in these studies.
|Recent Publications||Perlis RH, Adams DH, Fijal B, Sutton VK, Farmen M, Breier A, Houston JP. Genetic association study of treatment response with olanzapine/fluoxetine combination or lamotrigine in bipolar I depression. J Clin Psychiatry, in press.
Patel J, Pinals DA, Breier A: Schizophrenia and Other Psychoses. In: A Tasman, J Kay, JA Leiberman (eds), Psychiatry, (2 vols.). 3rd ed. 2008. Publisher: Wiley-Blackwell.
Breier A, Shekhar A. Innovative therapeutics for schizophrenia. Psychopharm Rev 44 (3):17-24, 2009